Advanced Filters
noise

A, Kuopio N Clinical Trials

A listing of A, Kuopio N clinical trials actively recruiting patients volunteers.

Found 11,558 clinical trials

A Long-term Follow up Study of EXG102-031 in Participants With wAMD

This is a long-term, safety and efficacy follow-up study of patients in the EXG102-031-111 gene therapy clinical trial for wAMD. Patients will complete visits from the parent study, and then into this long-term follow-up study for continuous safety monitoring for up to 5 years.

50 years of age All Phase N/A
J Jian Zhou, M.D., Ph.D.

A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG006A in patients with advanced solid tumors.

17 - 85 years of age All Phase 1/2
D Dong, M.D.

A Clinical Study of Glycerol Phenylbutyrate in Chinese Patients With Urea Cycle Disorders

Urea cycle disorders (UCD) are rare diseases in China, would lead to high mortality and disability, which require long-term management due to the recurrent symptoms. This multi-center, prospective, single-arm study was designed to assess the efficacy and safety of Glycerol Phenylbutyrate for Chinese pediatric patients with UCD, to provide the …

- 18 years of age All Phase N/A
D Dori Katz, DR

A Novel Robotic System for Motor-cognitive Exercise for Patients With Parkinson's Disease

The objective of this study is to test a gamified rehabilitation system in a sitting position involving robots and music for the benefit of individuals with Parkinson's disease (PD). This pilot experiment will involve the collection of both subjective user evaluation measures and objective motor and cognitive measures.

50 - 75 years of age All Phase N/A
B Berge Minassian, MD

A Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease

This study will test the safety and efficacy of multiple doses of ION283 administered as intrathecal (IT) injections by lumbar puncture (LP). All subjects will receive ION283. The dose level of 15 mg will be studied in all subjects.

10 - 18 years of age All Phase 1/2
V Vinod Ganju

A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors

This is an open-label, first-in-human, Phase I clinical study aimed at evaluating the safety, tolerability, PK, immunogenicity, and preliminary antitumor efficacy of AK138D1 in subjects being treated for advanced solid tumors.

18 - 75 years of age All Phase 1
Y Yiyi Yu

A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors

This study is an open-label, multi-centre, single-arm, phase I clinical study, to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of IMM2510 (an anti-PD-L1/VEGF bispecific antibody fusion protein) + IMM27M (a humanized Fc-engineered anti-CTLA-4 antibody) combination therapy in patients with advanced solid tumors.

18 - 75 years of age All Phase 1
F For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

A Prospective Natural History and Outcome Measure Validation Study of Congenital Myasthenic Syndromes

Background Congenital myasthenic syndromes (CMSs) are a group of inherited disorders that affect how the nerves communicate with muscles. These can cause many problems that affect how people can move and use their bodies. Objective This is a natural history study to learn more about how CMSs affect the body …

6 - 99 years of age All Phase N/A

Validation of Continuous Monitoring of Vital Signs in Children With a Connected Patch

Small connected devices monitoring vital signs do not exist in children although they could be very useful to monitor patients once they have left the pediatric intensive care unit (PICU) in order to early identify patients at risk of PICU readmission. The main objective of this study is to assess …

- 18 years of age All Phase N/A
Z ZHENGBO SONG, DOCTORATE

A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors

This is a Phase Ia/Ib, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and preliminary efficacy of HS387 in subjects with advanced solid tumors. It includes two parts: the dose escalation study (Phase Ia) and the dose expansion study (Phase Ib)

18 - 75 years of age All Phase 1

Simplify language using AI